Press release content from NewMediaWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from NewMediaWire
Press release content from NewMediaWire. The AP news staff was not involved in its creation.

AngioSoma has Repaid $469,000 of Notes

November 20, 2019 GMT
AngioSoma, Inc.
AngioSoma, Inc.

Houston, TX - ( NewMediaWire ) - November 20, 2019 - AngioSoma Inc. ( OTC: SOAN) (“AngioSoma” or the “Company”) today announced that holders of the Company’s 12% unsecured convertible notes in the principal amount of $469,000 maturing not later than June 30, 2020 (the “Notes”) elected to convert their Notes, resulting in $469,000 of the principal amount of the Notes being settled and reducing AngioSoma’s annual interest expense by approximately $56,000 through repayment of $469,000 of debt.

“The successful repayment of the majority of the Notes has strengthened our balance sheet and effectively left AngioSoma with substantially less long-term debt payable,” said Alex Blankenship, CEO of AngioSoma. “The additional funding received from the partial conversion of the Notes further strengthens our financial position as we continue to execute the roll-out of our Muscles4U workout enhancement products later this year.”


AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals™.  SomaCeuticals’s experienced team of industry first movers and enterprising visionaries has acquired a diversified supply of supplements, strong clinical, scientific and operating capabilities and leading product research and development infrastructure in order to create trusted products and brands in an expanding global market. 

Learn more at www.muscles4U.com and htttps://muscles4u.blogstop.com.  Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook


This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.


AngioSoma, Inc.

Alex Blankenship


(832) 781- 8521